You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 24, 2024

CATAPRES Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Catapres, and when can generic versions of Catapres launch?

Catapres is a drug marketed by Boehringer Ingelheim and Lavipharm and is included in two NDAs.

The generic ingredient in CATAPRES is clonidine. There are twenty-two drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the clonidine profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Catapres

A generic version of CATAPRES was approved as clonidine by DIFGEN PHARMS on August 18th, 2009.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for CATAPRES?
  • What are the global sales for CATAPRES?
  • What is Average Wholesale Price for CATAPRES?
Drug patent expirations by year for CATAPRES
Drug Prices for CATAPRES

See drug prices for CATAPRES

Recent Clinical Trials for CATAPRES

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Rigshospitalet, DenmarkPhase 2/Phase 3
Deventer ZiekenhuisPhase 3
Queen's University, BelfastPhase 3

See all CATAPRES clinical trials

US Patents and Regulatory Information for CATAPRES

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Boehringer Ingelheim CATAPRES clonidine hydrochloride TABLET;ORAL 017407-001 Approved Prior to Jan 1, 1982 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Lavipharm CATAPRES-TTS-1 clonidine SYSTEM;TRANSDERMAL 018891-001 Oct 10, 1984 AB RX Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Boehringer Ingelheim CATAPRES clonidine hydrochloride TABLET;ORAL 017407-002 Approved Prior to Jan 1, 1982 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for CATAPRES

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Boehringer Ingelheim CATAPRES clonidine hydrochloride TABLET;ORAL 017407-001 Approved Prior to Jan 1, 1982 ⤷  Sign Up ⤷  Sign Up
Boehringer Ingelheim CATAPRES clonidine hydrochloride TABLET;ORAL 017407-003 Approved Prior to Jan 1, 1982 ⤷  Sign Up ⤷  Sign Up
Boehringer Ingelheim CATAPRES clonidine hydrochloride TABLET;ORAL 017407-002 Approved Prior to Jan 1, 1982 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.